Page values for "Treximet"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | Sumatriptan / Naproxen |
| brand | String | Treximet |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Triptans|Triptan (5-HT1B/1D agonist)]] • [[:Category:NSAIDs|NSAID (naproxen)]] • [[:Category:Antimigraine_agents|Antimigraine agent]] • [[:Category:Fixed-dose_combinations|Fixed-dose combination]] |
| mechanism | String | '"`UNIQ--vote-000015CE-QINU`"' The dual-mechanism design exploits the inflammatory component of migraine that triptan monotherapy does not fully address. Risk of serotonin syndrome with SSRIs/SNRIs is theoretical but generally not seen clinically at triptan doses'"`UNIQ--ref-000015CF-QINU`"'. |
| uses | String | '"`UNIQ--vote-000015D0-QINU`"' |
| starting_dose | String | 1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours |
| preparations | String | 85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric) |
| fda_max | String | 2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Headache relief at 30-60 minutes |
| duration | String | 4-8 hours |
| halflife | String | Sumatriptan ~2.5 hours; naproxen 12-15 hours'"`UNIQ--ref-000015D1-QINU`"' |
| bioavailability | String | Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"' |
| pregnancy | String | Avoid; NSAID-class restriction after 20 weeks (FDA 2020) and limited triptan pregnancy data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use'"`UNIQ--ref-000015D3-QINU`"' |